AR072777A1 - Formas solidas de clorhidrato de bendamustina - Google Patents

Formas solidas de clorhidrato de bendamustina

Info

Publication number
AR072777A1
AR072777A1 ARP090101039A ARP090101039A AR072777A1 AR 072777 A1 AR072777 A1 AR 072777A1 AR P090101039 A ARP090101039 A AR P090101039A AR P090101039 A ARP090101039 A AR P090101039A AR 072777 A1 AR072777 A1 AR 072777A1
Authority
AR
Argentina
Prior art keywords
bendamustine
bendamustine hydrochloride
chlorhydrate
solid forms
degrees 2theta
Prior art date
Application number
ARP090101039A
Other languages
English (en)
Inventor
Martin Ian Cooper
Mark Eddleston
Laurent Courvoisier
Robert E Mckean
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051023&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072777(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of AR072777A1 publication Critical patent/AR072777A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Se describe una forma solida de clorhidrato de bendamustina que comprende clorhidrato de bendamustina, Forma 1 y/o clorhidrato de bendamustina, Forma 3 y/o clorhidrato de bendamustina, Forma 4 y/o clorhidrato de bendamustina amorfo, o una mezcla de ellas. La forma solida resultante de clorhidrato de bendamustina tiene un patron de difraccion de rayos X de polvo que contiene una o más de las siguientes reflexiones: 25,1; 24,9; 22,9; 22,0; y/o 14,1 +/- 0,2 grados 2theta; o 26,1; 27,9; y/o 28,1 +/- 0,2 grados 2theta; o 10,8; 15,5; 20,5; y/o 23,6 +/- 0,2 grados 2theta.
ARP090101039A 2008-03-26 2009-03-23 Formas solidas de clorhidrato de bendamustina AR072777A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3975208P 2008-03-26 2008-03-26

Publications (1)

Publication Number Publication Date
AR072777A1 true AR072777A1 (es) 2010-09-22

Family

ID=41051023

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101039A AR072777A1 (es) 2008-03-26 2009-03-23 Formas solidas de clorhidrato de bendamustina

Country Status (12)

Country Link
US (9) US20090264488A1 (es)
EP (2) EP3150197A1 (es)
JP (1) JP5536753B2 (es)
CN (3) CN103550159B (es)
AR (1) AR072777A1 (es)
CA (1) CA2718939A1 (es)
CL (1) CL2009000742A1 (es)
ES (1) ES2605205T3 (es)
HK (1) HK1220966A1 (es)
MX (2) MX2010010398A (es)
TW (1) TWI472515B (es)
WO (1) WO2009120386A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
ES2583804T3 (es) * 2007-10-09 2016-09-22 Us Worldmeds Llc Composiciones de codisolventes y métodos para la administración mejorada de agentes terapéuticos de dantroleno
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN104224703A (zh) * 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
WO2010144675A1 (en) * 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
EP2516404A4 (en) 2009-12-23 2013-04-17 Reddys Lab Ltd Dr PREPARATION OF BENDAMUSTINE AND ITS SALTS
RS55491B2 (sr) 2010-01-28 2020-11-30 Eagle Pharmaceuticals Inc Formulacije bendamustina
WO2011151087A1 (en) 2010-06-02 2011-12-08 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
JO3659B1 (ar) 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN101948437B (zh) * 2010-06-28 2012-08-29 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀的精制方法
EP2635558A4 (en) * 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
US20140142153A1 (en) * 2011-01-25 2014-05-22 Dr. Reddy's Laboratories, Inc. Bendamustine formulations
CN103443084A (zh) * 2011-01-31 2013-12-11 赛福伦公司 制备苯达莫司汀的方法
WO2013046223A1 (en) 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
CN102351799B (zh) * 2011-10-24 2014-02-26 江苏奥赛康药业股份有限公司 一种盐酸苯达莫司汀晶型及其制备方法
EP2617716A1 (en) 2012-01-18 2013-07-24 Arevipharma GmbH Process for the preparation of bendamustine hydrochloride and related compounds
CN104302291A (zh) 2012-03-20 2015-01-21 鹰制药股份有限公司 苯达莫司汀的制剂
JP6224064B2 (ja) 2012-03-20 2017-11-01 イーグル・ファーマシューティカルズ・インコーポレーテッド 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
WO2013150020A1 (en) 2012-04-03 2013-10-10 Synthon Bv Process for making bendamustine
DK2656843T3 (en) 2012-04-26 2015-04-20 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9801859B2 (en) * 2012-09-18 2017-10-31 Innopharma Licensing, Llc Bendamustine formulations
CA2890462A1 (en) 2012-11-12 2014-05-15 Ignyta, Inc. Bendamustine derivatives and methods of using same
EP2958554B1 (en) 2013-02-19 2018-06-06 Synthon BV Stable compositions of bendamustine
US9315469B2 (en) 2013-03-14 2016-04-19 Johnson Matthey Public Limited Company Process for drying bendamustine hydrochloride monohydrate
WO2014170769A2 (en) * 2013-04-15 2014-10-23 Shilpa Medicare Limited Bendamustine lyophilized pharmaceutical compositions
JP6571657B2 (ja) 2013-08-27 2019-09-04 ボウドウリス バシリオス ベンダムスチンの薬学的組成物
CN106102722A (zh) * 2014-03-13 2016-11-09 V·沃道里斯 苯达莫司汀固体分散体和连续输液
EP2985038A1 (en) 2014-08-12 2016-02-17 Azad Pharma AG Lyophilized API preparation
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
US9603930B2 (en) 2014-12-04 2017-03-28 Navinta, Llc Liquid bendamustine formulation
KR102066242B1 (ko) * 2015-06-09 2020-01-14 리바이오틱스, 인코퍼레이티드 미생물상 복원 치료(mrt) 조성물 및 제조 방법
US10905677B2 (en) 2016-08-31 2021-02-02 Navinta, Llc Bendamustine solution formulations
US11826466B2 (en) 2016-08-31 2023-11-28 Navinta, Llc Bendamustine solution formulations
BR112020006360A2 (pt) 2017-10-05 2020-09-24 Tube Pharmaceuticals Gmbh composição para uso como um medicamento e composição farmacêutica oral que compreendem bendamustina ou um sal ou solvato farmaceuticamente aceitáveis, uso e método de distribuição de bendamustina ou um sal ou solvato farmaceuticamente aceitáveis, método de tratamento de uma doença ou disfunção em um sujeito com necessidade do mesmo
TWI690514B (zh) * 2017-11-07 2020-04-11 大陸商江蘇恒瑞醫藥股份有限公司 一種鹽酸苯達莫司汀的晶體及其製備方法
EA037673B1 (ru) * 2018-07-04 2021-04-29 Тютор С.А.С.И.Ф.И.А. Способ получения фармацевтической композиции, содержащей бендамустин, фармацевтическая композиция бендамустина
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2023067188A1 (en) 2021-10-22 2023-04-27 Project Pharmaceutics Gmbh Liquid pharmaceutical formulation

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE159877C (es) *
DE159289C (es) 1903-10-08 1905-03-16
DE293808C (es)
DD80967A (es)
DE34727C (de) Ch. H. TH. HAVEMANN in Paris, 16 rue Bleue Verfahren zur direkten Gewinnung metallischen Bleis
DE80967C (es)
DD34727A1 (de) 1963-12-21 1964-12-28 Dietrich Krebs Verfahren zur Herstellung von 1-Stellung substituierten [5-Bis-(chloräthyl)-amino-benzimidazolyl-(2)]-alkancarbonsäuren
YU33730B (en) 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
DD159289A1 (de) * 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US5227374A (en) 1982-11-12 1993-07-13 Mead Johnson & Company Lyophilized cyclophosphamide
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US4659699A (en) 1983-08-22 1987-04-21 Cetus-Ben Venue Therapeutics Process for freeze drying cyclophosphamide
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US4879286A (en) 1987-01-28 1989-11-07 Lyphomed, Inc. Cyclophosphamide
DE3907079A1 (de) 1988-03-19 1989-09-28 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
ATE65402T1 (de) 1988-03-19 1991-08-15 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5036060A (en) 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
CA2001552C (en) 1988-11-14 1997-07-22 The Upjohn Company Cyclophosphamide - sodium bicarbonate lyophilizates
US5066647A (en) 1989-04-20 1991-11-19 Erbamont, Inc. Cyclophosphamide - alanine lyophilizates
US5051257A (en) 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
DD293808A5 (de) 1990-04-23 1991-09-12 Zi Fuer Mikrobiologie Uns Experimentelle Therapie,De Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern
US5268368A (en) 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
ES2091684T3 (es) * 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5418223A (en) 1993-05-20 1995-05-23 Erbamont, Inc. Method for lyophilization of cyclophosphamide and product
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5741523A (en) * 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
EP0859779A4 (en) 1995-08-31 2000-04-12 Smithkline Beecham Corp INTERLEUKIN CONVERSION ENZYME AND APOPTOSIS
EP0780386B1 (en) 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
AU8282798A (en) 1997-07-01 1999-01-25 Atherogenics, Inc. Antioxidant enhancement of therapy for hyperproliferative conditions
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
WO2000002555A1 (en) * 1998-07-09 2000-01-20 Nardella Francis A Methods and compositions for the treatment of chronic lymphocytic leukemia
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
AUPQ849900A0 (en) 2000-06-30 2000-07-27 Dbl Australia Pty Ltd. Injectable composition
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
HUP0400683A2 (hu) * 2000-12-11 2004-06-28 Takeda Chemical Industries, Ltd. HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény
US20040058956A1 (en) * 2000-12-11 2004-03-25 Yohko Akiyama Pharmaceutical composition having an improved water solubility
WO2002080996A1 (de) * 2001-04-03 2002-10-17 Franz Herbst Medizinisches implantat und verfahren zu seiner herstellung
JP4549059B2 (ja) * 2001-10-15 2010-09-22 ヘモテック アーゲー 再狭窄を防止するためのステントのコーテイング
US6613927B1 (en) 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
US6780324B2 (en) 2002-03-18 2004-08-24 Labopharm, Inc. Preparation of sterile stabilized nanodispersions
CN100561229C (zh) 2002-03-22 2009-11-18 克里斯蒂安·施特拉卡 细胞能力检验
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
SI1501566T1 (sl) 2002-05-09 2008-12-31 Hemoteq Ag S hemakompatibilnim slojem prekriti medicinski proizvodi, njihova izdelava in uporaba
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
JP2006512409A (ja) 2002-10-31 2006-04-13 ユーエムディー， インコーポレイテッド 薬物送達用治療組成物で被覆上皮に対するもの及びそれを介するもの
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
WO2004074325A2 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
MXPA05013865A (es) * 2003-07-25 2006-02-28 Wyeth Corp Formulaciones liofilizadas de cci-779.
MX2007005361A (es) 2004-11-05 2008-01-11 Cephalon Inc Tratamientos para cancer.
CN101060832A (zh) 2004-11-22 2007-10-24 维纳斯药业有限公司 非水液体肠胃外醋氯芬酸配方
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
CN101119708B (zh) * 2005-01-14 2014-12-24 赛福伦公司 苯达莫司汀冻干药物组合物
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
EP1909824B1 (en) 2005-04-08 2011-05-18 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ITUD20070130A1 (it) 2007-07-23 2009-01-24 C M E Spa Sa Macchina e procedimento per la produzione di elementi strutturali per l'edilizia in materiale cementizio aventi uno o piu' inserti in materiale polimerico
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN104224703A (zh) 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
WO2010126676A1 (en) 2009-04-28 2010-11-04 Cephalon, Inc. Oral formulations of bendamustine

Also Published As

Publication number Publication date
ES2605205T3 (es) 2017-03-13
US8445524B2 (en) 2013-05-21
MX339878B (es) 2016-06-15
US20170071913A1 (en) 2017-03-16
TWI472515B (zh) 2015-02-11
TW200944508A (en) 2009-11-01
WO2009120386A3 (en) 2009-12-03
US8883836B2 (en) 2014-11-11
US20200323824A1 (en) 2020-10-15
US20190015390A1 (en) 2019-01-17
US10039750B2 (en) 2018-08-07
EP2271315A2 (en) 2011-01-12
CN101980698A (zh) 2011-02-23
EP3150197A1 (en) 2017-04-05
US20130245086A1 (en) 2013-09-19
US20090264488A1 (en) 2009-10-22
US10517852B2 (en) 2019-12-31
US20160159748A1 (en) 2016-06-09
HK1220966A1 (zh) 2017-05-19
US20150051258A1 (en) 2015-02-19
CN103550159B (zh) 2016-02-10
US20140187598A1 (en) 2014-07-03
US8669279B2 (en) 2014-03-11
JP5536753B2 (ja) 2014-07-02
JP2011515472A (ja) 2011-05-19
EP2271315B1 (en) 2016-09-14
CN103550159A (zh) 2014-02-05
MX2010010398A (es) 2010-12-20
US20120071532A1 (en) 2012-03-22
CN101980698B (zh) 2013-10-16
CN105693620A (zh) 2016-06-22
CL2009000742A1 (es) 2009-11-13
CA2718939A1 (en) 2009-10-01
WO2009120386A2 (en) 2009-10-01
US9533955B2 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
AR072777A1 (es) Formas solidas de clorhidrato de bendamustina
GT200600371A (es) Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
CR11267A (es) Preparacion solida que contiene alogliptina y clorhidrato de metformina
CR8647A (es) Forma cristalina delta-d de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmacueticas que la contienen
AR063347A1 (es) Formas cristalinas de docetaxel y proceso para su preparacion
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
NO20075345L (no) Sublingual belagt tablett
PE20140698A1 (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2, 4-diamina
PA8759401A1 (es) Forma cristalina delhemihidrato
RS54386B1 (en) ANTIVIRAL UNITS
ECSP088597A (es) Sal de sulfato de hidrógeno novedosa
GT200600227A (es) Formas solidas cristalinas de tigeciclina y metodos para preparar las mismas
CR11029A (es) Anticuerpos en contra de erbb3 y usos de los mismos
CR8645A (es) Forma cristalina delta de clorhidrato de ivabradina, su procedimiento de produccion y composiciones farmacueticas que la contienen
UY33754A (es) Monobactamas
AR082804A1 (es) Formas cristalinas de un inhibidor del factor xa
UA108199C2 (uk) АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
CY1113916T1 (el) Παραγωγα ετεροαρυλο πυρρολιδινυλο και πιπεριδινυλο κετονης
RS54158B1 (en) AMILOID BINDING AGENTS
AR098888A1 (es) Composición para el cuidado oral
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
CO6430482A2 (es) Forjado para plantas de construcción
BRPI0615332A2 (pt) Composto, uso de um composto, ingrediente perfumante, e, artigo perfumado
AR064219A1 (es) Cuerpo moldeado que contiene titanio
ECSP109874A (es) Nuevos compuestos 892

Legal Events

Date Code Title Description
FC Refusal